This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Coherus (CHRS), Junshi Announce Positive NSCLC Study Results
by Zacks Equity Research
Coherus BioSciences (CHRS) and partner Junshi announce positive data from a late-stage study on toripalimab for the first-line treatment of NSCLC.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -60.00% and 6.05%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Jun 7, 2021
by Zacks Equity Research
Companies in the news are: REGN, CHRS, SENS, CGEM
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -2733.33% and -15.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Coherus BioSciences (CHRS) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -5.71% and -5.76%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
What's in Store for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.
Coherus BioSciences (CHRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Coherus BioSciences (CHRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Coherus BioSciences (CHRS) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Coherus BioSciences (CHRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Coherus BioSciences (CHRS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CHRS or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus BioSciences (CHRS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Check These 7 Top-Ranked Stocks With Solid Net Profit Margins
by Anirudha Bhagat
Let's take a look at the seven top-ranked stocks with impressive net profit margins for a winning portfolio.
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Coherus BioSciences, Bluerock Residential Growth REIT, Huntington Ingalls Industries and Installed Building Products
Signs of Coronavirus Slowdown Pep Up Wall Street: 5 Winners
by Tirthankar Chakraborty
Wall Street continues to build on a steep rebound in the previous session after lockdown strategy stabilized coronavirus outbreak in the United States and abroad.
Is Coherus BioSciences (CHRS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Coherus BioSciences (CHRS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities
by Zacks Equity Research
Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities